STAAR Surgical Company $STAA Shares Sold by WINTON GROUP Ltd

WINTON GROUP Ltd reduced its position in shares of STAAR Surgical Company (NASDAQ:STAA) by 27.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 138,408 shares of the medical instruments supplier’s stock after selling 52,120 shares during the quarter. WINTON GROUP Ltd owned 0.28% of STAAR Surgical worth $2,322,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Pinnacle Investment Management Ltd acquired a new position in STAAR Surgical during the first quarter worth $1,155,000. Strs Ohio purchased a new stake in shares of STAAR Surgical during the first quarter worth about $190,000. Assenagon Asset Management S.A. raised its position in shares of STAAR Surgical by 213.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 164,088 shares of the medical instruments supplier’s stock worth $2,753,000 after purchasing an additional 111,686 shares during the last quarter. Caxton Associates LLP acquired a new position in shares of STAAR Surgical during the 1st quarter worth about $1,051,000. Finally, Atika Capital Management LLC purchased a new position in STAAR Surgical in the 2nd quarter valued at about $275,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on STAA. Canaccord Genuity Group reissued a “hold” rating and set a $30.75 target price on shares of STAAR Surgical in a report on Tuesday. Piper Sandler reaffirmed a “neutral” rating on shares of STAAR Surgical in a research note on Monday, October 27th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of STAAR Surgical in a research note on Wednesday, October 8th. Ten analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, STAAR Surgical has an average rating of “Reduce” and a consensus target price of $21.13.

Insider Buying and Selling at STAAR Surgical

In other news, major shareholder Broadwood Partners, L.P. purchased 797,486 shares of the business’s stock in a transaction dated Friday, November 21st. The stock was acquired at an average price of $27.86 per share, for a total transaction of $22,217,959.96. Following the acquisition, the insider directly owned 15,019,491 shares of the company’s stock, valued at approximately $418,443,019.26. This represents a 5.61% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have purchased 1,500,000 shares of company stock valued at $41,061,615. Corporate insiders own 0.59% of the company’s stock.

STAAR Surgical Stock Performance

NASDAQ STAA opened at $25.39 on Wednesday. The stock’s fifty day moving average is $26.29 and its two-hundred day moving average is $23.49. The firm has a market capitalization of $1.26 billion, a P/E ratio of -13.02 and a beta of 1.01. STAAR Surgical Company has a fifty-two week low of $13.50 and a fifty-two week high of $30.81.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.